Research location
Freiburg im Breisgau
Baden-Wurttemberg, Germany
Advertisement
Research activity in Freiburg im Breisgau
Baden-Wurttemberg, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 126 trials and 130 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Freiburg im Breisgau
126 linked trials · page 1 of 3A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation
RECRUITING
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298 · 2026-01-30 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation
RECRUITING
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLCNCT06810609 · 2025-04-20 · 1 site observation
RECRUITING
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsNCT06726148 · 2025-04-03 · 1 site observation
RECRUITING
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNCT06597019 · 2024-12-09 · 1 site observation
RECRUITING
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGNCT06712628 · 2024-11-07 · 1 site observation
RECRUITING
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)NCT06081244 · 2024-10-10 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation
RECRUITING
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · 2024-02-05 · 1 site observation
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 1 site observation
RECRUITING
Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rtNCT06330909 · 2022-08-18 · 1 site observation
RECRUITING
Praegnant Breast Cancer: Early/Advanced/MetastaticNCT02338167 · 2014-06-01 · 1 site observation
RECRUITING
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseNCT07048197 · 2025-06-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisNCT06655896 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961 · 2023-11-23 · 1 site observation
COMPLETED
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.NCT05985915 · 2023-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
In-vivo Wear Behaviour of AS Coated Versus Uncoated Columbus® Total Knee ProsthesisNCT05509972 · 2023-04-06 · 1 site observation
TERMINATED
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyNCT04931979 · 2022-10-20 · 1 site observation
UNKNOWN
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeNCT05350072 · 2022-07-28 · 1 site observation
COMPLETED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)NCT05288166 · 2022-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.NCT04990284 · 2021-11-29 · 1 site observation
COMPLETED
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisNCT04926818 · 2021-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)NCT04700124 · 2021-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT04699188 · 2021-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · 2020-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152 · 2020-09-30 · 1 site observation
TERMINATED
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCNCT04565054 · 2020-09-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Real-life Pan-HER-blockade With NeratinibNCT04388384 · 2020-07-02 · 1 site observation
COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · 2020-05-22 · 1 site observation
TERMINATED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)NCT04233879 · 2020-02-28 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation
TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · 2019-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromeNCT03905525 · 2019-10-01 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation
TERMINATED
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · 2019-07-02 · 2 site observations
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation
COMPLETED
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabNCT03875729 · 2019-04-05 · 1 site observation
COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782 · 2019-02-28 · 1 site observation
COMPLETED
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03750552 · 2019-01-24 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.